Adjuvant Capital

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Codagenix Inc., established in 2009 and headquartered in Farmingdale, New York, specializes in developing live-attenuated viral vaccines using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. This technology involves the rational design of entire viral genomes via synthetic biology to create safe and effective vaccines for various human diseases such as influenza, dengue, respiratory syncytial virus, polio, and others. Additionally, Codagenix offers agricultural and companion animal vaccines.

InDevR, Inc. is a biotechnology company based in Boulder, Colorado, specializing in the development and marketing of life science instrumentation and assay products focused on the analysis of viruses and microorganisms. Established in 2002, InDevR offers a range of innovative technologies, including the Virus Counter for virus quantification, the FluChip for rapid pathogen detection, and the ViroPrep Allantoic Influenza sample cleanup kit. The company also provides the miPLEX system for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for photo-polymerization activation on microarrays. InDevR's products are designed to enhance vaccine characterization and facilitate the research, development, and manufacturing of vaccines, particularly in tracking seasonal and emerging influenza viruses.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

Frontier Nutrition, Inc. is a company dedicated to developing and manufacturing nutritious food products tailored for families in low and middle-income communities worldwide. Founded in 2016, the company focuses on addressing malnutrition, particularly among mothers and young children, by providing affordable and convenient food options. Their product offerings are based on research in pediatric nutrition and behavioral marketing, ensuring that recipes are not only nutritionally optimized but also appealing in taste and price. By localizing their recipes to fit traditional diets, Frontier Nutrition aims to make a significant impact on public health in frontier markets, where access to healthcare, clean water, and transportation can be limited. The company operates from its base in New Haven, Connecticut, and is committed to fostering sustainable living standards for underserved populations.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Codagenix Inc., established in 2009 and headquartered in Farmingdale, New York, specializes in developing live-attenuated viral vaccines using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. This technology involves the rational design of entire viral genomes via synthetic biology to create safe and effective vaccines for various human diseases such as influenza, dengue, respiratory syncytial virus, polio, and others. Additionally, Codagenix offers agricultural and companion animal vaccines.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

InDevR, Inc. is a biotechnology company based in Boulder, Colorado, specializing in the development and marketing of life science instrumentation and assay products focused on the analysis of viruses and microorganisms. Established in 2002, InDevR offers a range of innovative technologies, including the Virus Counter for virus quantification, the FluChip for rapid pathogen detection, and the ViroPrep Allantoic Influenza sample cleanup kit. The company also provides the miPLEX system for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for photo-polymerization activation on microarrays. InDevR's products are designed to enhance vaccine characterization and facilitate the research, development, and manufacturing of vaccines, particularly in tracking seasonal and emerging influenza viruses.

X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.